Simulations Plus (NASDAQ:SLP) Given “Market Perform” Rating at JMP Securities

JMP Securities reiterated their market perform rating on shares of Simulations Plus (NASDAQ:SLP) in a report issued on Wednesday morning,Benzinga reports.

A number of other equities research analysts have also recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a report on Tuesday, June 3rd. KeyCorp boosted their price target on shares of Simulations Plus from $32.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, April 16th. Craig Hallum cut their target price on shares of Simulations Plus from $45.00 to $36.00 and set a “buy” rating for the company in a research report on Friday, June 13th. Finally, Wall Street Zen upgraded shares of Simulations Plus from a “sell” rating to a “hold” rating in a research report on Monday, April 28th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $41.25.

Simulations Plus Stock Down 1.3%

Simulations Plus stock opened at $18.08 on Wednesday. Simulations Plus has a 52 week low of $17.97 and a 52 week high of $49.71. The company’s 50 day moving average price is $30.39 and its two-hundred day moving average price is $29.94. The stock has a market cap of $363.59 million, a P/E ratio of 51.66 and a beta of 0.97.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.25 by $0.06. The firm had revenue of $22.43 million for the quarter, compared to analysts’ expectations of $21.93 million. Simulations Plus had a net margin of 9.18% and a return on equity of 7.86%. The company’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.20 EPS. On average, equities analysts anticipate that Simulations Plus will post 1.09 EPS for the current year.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $33.51, for a total value of $670,200.00. Following the completion of the transaction, the director now directly owns 3,344,157 shares of the company’s stock, valued at $112,062,701.07. This represents a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 19.40% of the company’s stock.

Institutional Investors Weigh In On Simulations Plus

A number of institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp boosted its holdings in Simulations Plus by 53.6% in the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock worth $34,000 after purchasing an additional 427 shares during the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Simulations Plus during the 4th quarter valued at $39,000. Fifth Third Bancorp raised its position in shares of Simulations Plus by 33.8% during the 1st quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company’s stock valued at $36,000 after purchasing an additional 375 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Simulations Plus by 42.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company’s stock valued at $72,000 after purchasing an additional 764 shares during the period. Finally, AlphaQuest LLC raised its position in shares of Simulations Plus by 502.9% during the 4th quarter. AlphaQuest LLC now owns 2,689 shares of the technology company’s stock valued at $75,000 after purchasing an additional 2,243 shares during the period. Hedge funds and other institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.